Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.47102/annals-acadmedsg.20244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular safety of osteoanabolic agents.
J Bone Miner Metab
January 2025
Toranomon Hospital Endocrine Center, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Purpose: Several osteoanabolic agents have been developed to build new bone more efficiently than anti-resorptive drugs. Among them, romosozumab, an anti-sclerostin antibody, is a potent pharmacological tool to prevent fractures in osteoporosis patients. The efficacy of romosozumab in preventing osteoporotic fractures is robust.
View Article and Find Full Text PDFAetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult.
J Endocrinol Invest
January 2025
Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Aim: This review aims to overview factors contributing to TAO development and addresses the targeted diagnostic work-up and treatment management in adult thalassemic patients.
Results: Osteoporosis management in Thalassemia is challenging because several factors contributing to its pathogenesis should be considered and controlled starting from child- hood. A multidisciplinary approach is crucial.
[Certain key questions in the diagnosis and treatment of primary osteoporosis and other disorders related to abnormal calcium and phosphorus metabolism].
Zhonghua Yi Xue Za Zhi
January 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200025, China.
When diagnosing and treating primary osteoporosis and various calcium-phosphorus metabolism disorders, we must pay attention to some key points: diagnosing primary osteoporosis only after excluding secondary factors; understanding the features of various calcium supplements and anti-osteoporosis drugs; and selecting appropriate medications; foreseeing the changes in calcium-phosphorus metabolism after using anti-osteoporosis drugs. This article delves into the aforementioned key issues in the diagnosis and treatment of primary osteoporosis and various disorders of calcium and phosphorus metabolism. It emphasizes the pathophysiological mechanisms, diagnostic criteria, rational drug use, and precautions for primary osteoporosis and various disorders of calcium and phosphorus metabolism, aiming to enhance the level of disease diagnosis and treatment through a holistic thinking.
View Article and Find Full Text PDFScreening of orthopedic medicines identifies raloxifene hydrochloride as a novel ferroptosis inhibitor for spinal cord injury therapy.
Int Immunopharmacol
December 2024
Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China; Zhejiang Provincial Key Laboratory of Orthopaedics, Wenzhou, Zhejiang Province, China; The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang Province, China. Electronic address:
Spinal cord injury (SCI) is a severe condition that can lead to irreversible central nervous system damage. Spinal cord injury patients frequently present with coexisting orthopedic conditions, and many of them also have underlying bone and joint diseases. Recent studies have identified ferroptosis as a significant contributor that exacerbates the progression of spinal cord injury.
View Article and Find Full Text PDFEvaluating the Anti-Osteoporotic Potential of Mediterranean Medicinal Plants: A Review of Current Evidence.
Pharmaceuticals (Basel)
October 2024
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.
Article Synopsis
- - Bones act as reservoirs for essential minerals and cells while protecting organs and shaping the body, but osteoporosis poses a significant threat to overall quality of life.
- - There is increasing interest in using natural products and Mediterranean medicinal plants as alternatives for treating osteoporosis and preventing related fractures, though their use remains limited.
- - This article highlights seven specific Mediterranean plants and their active compounds (e.g., xanthotoxin, polyphenols) that show promise as anti-osteoporosis agents, suggesting a need for more research in developing plant-based therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!